<?xml version="1.0" encoding="utf-8"?>
<Label drug="Xarelto" setid="10db92f9-2300-4a80-836b-673e1ae91610">
<Text><Section name="BOXED WARNING SECTION" id="34066-1">
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA 

 WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA 

 See full prescribing information for complete boxed warning 

 (A) Premature discontinuation of XARELTO increases the risk of thrombotic events 

 Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.3 , 2.8 , 5.1 , 14.1 ). 

 (B) Spinal/epidural hematoma 

 Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis ( 5.2 , 5.3 , 6.2 ). 

 Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated ( 5.3 ). 

 A. Premature discontinuation of XARELTO increases the risk of thrombotic events 

 Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3 , 2.8) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . 

 B. Spinal/epidural hematoma 

 Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: 

 use of indwelling epidural catheters 

 concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants 

 a history of traumatic or repeated epidural or spinal punctures 

 a history of spinal deformity or spinal surgery 

 optimal timing between the administration of XARELTO and neuraxial procedures is not known 

 [see Warnings and Precautions (5.2 , 5.3) and Adverse Reactions (6.2) ]. 

 Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3) ] . 

 Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.3) ] .</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION 

 Nonvalvular Atrial Fibrillation : 
 For patients with CrCl &gt;50 mL/min: 20 mg orally, once daily with the evening meal ( 2.4 ) 
 For patients with CrCl 15 – 50 mL/min: 15 mg orally, once daily with the evening meal ( 2.4 ) 

 Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment ( 2.5 ) 

 Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment ( 2.6 ) 

 Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food ( 2.7 ) 

 2.1 Recommended Dosage 

 Indication 
 Dosage 

 Reduction in Risk of Stroke in Nonvalvular Atrial Fibrillation (2.4) 

 CrCl &gt;50 mL/min: 
 20 mg once daily with the evening meal 

 CrCl 15 to 50 mL/min: 
 15 mg once daily with the evening meal 

 Treatment of DVT (2.5) Treatment of PE (2.5) 

 15 mg twice daily with food, for first 21 days 

     ▼after 21 days, transition to ▼ 

 20 mg once daily with food, for remaining treatment 

 Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE (2.6) 

 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment 

 Prophylaxis of DVT Following Hip or Knee Replacement Surgery (2.7) 

 Hip replacement: 
 10 mg once daily with or without food for 35 days 

 Knee replacement: 
 10 mg once daily with or without food for 12 days 

 2.2 Important Food Effect Information 

 The 15 mg and 20 mg XARELTO tablets should be taken with food, while the 10 mg tablet can be taken with or without food [see Clinical Pharmacology (12.3) ] . 
 In the nonvalvular atrial fibrillation efficacy study XARELTO was taken with the evening meal. 

 2.3 Switching to and from XARELTO 

 Switching from Warfarin to XARELTO - When switching patients from warfarin to XARELTO, discontinue warfarin and start XARELTO as soon as the International Normalized Ratio (INR) is below 3.0 to avoid periods of inadequate anticoagulation. 

 Switching from XARELTO to Warfarin - No clinical trial data are available to guide converting patients from XARELTO to warfarin. XARELTO affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken. 

 Switching from XARELTO to Anticoagulants other than Warfarin - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken [see Drug Interactions (7.4) ] . 

 Switching from Anticoagulants other than Warfarin to XARELTO - For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, stop the infusion and start XARELTO at the same time. 

 2.4 Nonvalvular Atrial Fibrillation 

 For patients with creatinine clearance (CrCl) &gt;50 mL/min, the recommended dose of XARELTO is 20 mg taken orally once daily with the evening meal. For patients with CrCl 15 to 50 mL/min, the recommended dose is 15 mg once daily with the evening meal [see Use in Specific Populations (8.6) ] . 

 2.5 Treatment of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) 

 The recommended dose of XARELTO for the initial treatment of acute DVT and/or PE is 15 mg taken orally twice daily with food for the first 21 days. After this initial treatment period, the recommended dose of XARELTO is 20 mg taken orally once daily with food, at approximately the same time each day [see Clinical Studies (14.2) ] . 

 2.6 Reduction in the Risk of Recurrence of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) 

 The recommended dose of XARELTO for the reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatment in patients at continued risk of DVT and/or PE is 10 mg taken orally once daily with or without food [see Clinical Studies (14.3) ]. 

 2.7 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery 

 The recommended dose of XARELTO is 10 mg taken orally once daily with or without food. The initial dose should be taken 6 to 10 hours after surgery provided that hemostasis has been established [see Dosage and Administration (2.8) ] . 

 For patients undergoing hip replacement surgery, treatment duration of 35 days is recommended. 
 For patients undergoing knee replacement surgery, treatment duration of 12 days is recommended. 

 2.8 Discontinuation for Surgery and other Interventions 

 If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of bleeding [see Warnings and Precautions (5.2) ] . In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO, the increased risk of bleeding should be weighed against the urgency of intervention. XARELTO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established, noting that the time to onset of therapeutic effect is short [see Warnings and Precautions (5.1) ] . If oral medication cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant. 

 2.9 Missed Dose 

 If a dose of XARELTO is not taken at the scheduled time, administer the dose as soon as possible on the same day as follows: 

 For patients receiving 15 mg twice daily: The patient should take XARELTO immediately to ensure intake of 30 mg XARELTO per day. In this particular instance, two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day. 
 For patients receiving 20 mg, 15 mg or 10 mg once daily: The patient should take the missed XARELTO dose immediately. 

 2.10 Administration Options 

 For patients who are unable to swallow whole tablets, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and mixed with applesauce immediately prior to use and administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should be immediately followed by food [see Dosage and Administration (2.2 , 2.4 , 2.5) and Clinical Pharmacology (12.3) ] . 

 Administration via nasogastric (NG) tube or gastric feeding tube: After confirming gastric placement of the tube, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and suspended in 50 mL of water and administered via an NG tube or gastric feeding tube. Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding [see Clinical Pharmacology (12.3) ] . 
 Crushed 10 mg, 15 mg or 20 mg XARELTO tablets are stable in water and in applesauce for up to 4 hours. An in vitro compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing.</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS 

 XARELTO is contraindicated in patients with: 

 active pathological bleeding [see Warnings and Precautions (5.2) ] 

 severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) [see Adverse Reactions (6.2) ] 

 Active pathological bleeding ( 4 ) 
 Severe hypersensitivity reaction to XARELTO ( 4 )</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 Risk of bleeding: XARELTO can cause serious and fatal bleeding. Promptly evaluate signs and symptoms of blood loss. ( 5.2 ) 
 Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery. Promptly evaluate signs and symptoms of blood loss. ( 5.7 ) 
 Prosthetic heart valves: XARELTO use not recommended ( 5.8 ) 

 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation 

 Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients. If XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3 , 2.8) and Clinical Studies (14.1) ] . 

 5.2 Risk of Bleeding 

 XARELTO increases the risk of bleeding and can cause serious or fatal bleeding. In deciding whether to prescribe XARELTO to patients at increased risk of bleeding, the risk of thrombotic events should be weighed against the risk of bleeding. 
 Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO in patients with active pathological hemorrhage. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years. 
 Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y 12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions (7.4) ] , selective serotonin reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors. 
 Concomitant use of drugs that are known combined P-gp and strong CYP3A4 inhibitors increases rivaroxaban exposure and may increase bleeding risk [see Drug Interactions (7.2) ] . 

 Reversal of Anticoagulant Effect 

 A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable [see Clinical Pharmacology (12.3) ] . Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. Partial reversal of prothrombin time prolongation has been seen after administration of prothrombin complex concentrates (PCCs) in healthy volunteers. The use of other procoagulant reversal agents like activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (rFVIIa) has not been evaluated. 

 5.3 Spinal/Epidural Anesthesia or Puncture 

 When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning ] . 
 To reduce the potential risk of bleeding associated with the concurrent use of XARELTO and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of XARELTO [see Clinical Pharmacology (12.3) ] . Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of XARELTO is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. 
 An indwelling epidural or intrathecal catheter should not be removed before at least 2 half-lives have elapsed (i.e., 18 hours in young patients aged 20 to 45 years and 26 hours in elderly patients aged 60 to 76 years), after the last administration of XARELTO [see Clinical Pharmacology (12.3) ] . The next XARELTO dose should not be administered earlier than 6 hours after the removal of the catheter. If traumatic puncture occurs, delay the administration of XARELTO for 24 hours. 
 Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae. 

 5.4 Use in Patients with Renal Impairment 

 Nonvalvular Atrial Fibrillation 

 Periodically assess renal function as clinically indicated (i.e., more frequently in situations in which renal function may decline) and adjust therapy accordingly [see Dosage and Administration (2.4) ] . Consider dose adjustment or discontinuation of XARELTO in patients who develop acute renal failure while on XARELTO [see Use in Specific Populations (8.6) ]. 

 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE 

 Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population [see Use in Specific Populations (8.6) ] . 

 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery 

 Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Patients who develop acute renal failure while on XARELTO should discontinue the treatment [see Use in Specific Populations (8.6) ]. 

 5.5 Use in Patients with Hepatic Impairment 

 No clinical data are available for patients with severe hepatic impairment. 
 Avoid use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy since drug exposure and bleeding risk may be increased [see Use in Specific Populations (8.7) ] . 

 5.6 Use with P-gp and Strong CYP3A4 Inhibitors or Inducers 

 Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A4 inhibitors [see Drug Interactions (7.2) ] . 
 Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A4 inducers [see Drug Interactions (7.3) ] . 

 5.7 Risk of Pregnancy-Related Hemorrhage 

 In pregnant women, XARELTO should be used only if the potential benefit justifies the potential risk to the mother and fetus. XARELTO dosing in pregnancy has not been studied. The anticoagulant effect of XARELTO cannot be monitored with standard laboratory testing nor readily reversed. Promptly evaluate any signs or symptoms suggesting blood loss (e.g., a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress). 

 5.8 Patients with Prosthetic Heart Valves 

 The safety and efficacy of XARELTO have not been studied in patients with prosthetic heart valves. Therefore, use of XARELTO is not recommended in these patients. 

 5.9 Acute PE in Hemodynamically Unstable Patients or Patients Who Require Thrombolysis or Pulmonary Embolectomy 

 Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS 

 Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use ( 7.2 , 7.3 ) 
 Anticoagulants: Avoid concomitant use ( 7.4 ) 

 7.1 General Inhibition and Induction Properties 

 Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding. Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events. 

 7.2 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems 

 Interaction with Combined P-gp and Strong CYP3A4 Inhibitors 

 Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ] . 
 Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk [see Clinical Pharmacology (12.3) ] . 

 Interaction with Combined P-gp and Moderate CYP3A4 Inhibitors in Patients with Renal Impairment 

 XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ] . 

 7.3 Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems 

 Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ] . 

 7.4 Anticoagulants and NSAIDs/Aspirin 

 Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3) ]. 

 Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2) ] .</Section>
</Text><Sentences>
<Sentence id="36" LabelDrug="Xarelto" section="34066-1">
<SentenceText>Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture .</SentenceText>
</Sentence>
<Sentence id="37" LabelDrug="Xarelto" section="34066-1">
<SentenceText>Premature discontinuation of any oral anticoagulant , including XARELTO , increases the risk of thrombotic events .</SentenceText>
</Sentence>
<Sentence id="38" LabelDrug="Xarelto" section="34066-1">
<SentenceText>use of indwelling epiduralcatheters . concomitant use of other drugs that affect hemostasis , such as nnon-steroidal anti-inflammatory drugs ( NSAIDs ) , platelet inhibitors , other anticoagulants . a history of traumatic or repeated epidural or spinal punctures . a history of spinal deformity or spinal surgery . optimal timing between the administration of XXARELTOand neuraxial procedures is not known . see Warnings and Precautions ( 5.2 , 5.3 ) and Adverse Reactions ( 6.2 ) .</SentenceText>
</Sentence>
<Sentence id="39" LabelDrug="Xarelto" section="34068-7">
<SentenceText>For unfractionated heparin being administered by continuous infusion , stop the infusion and start XARELTO at the same time .</SentenceText>
</Sentence>
<Sentence id="40" LabelDrug="Xarelto" section="34068-7">
<SentenceText>One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken .</SentenceText>
</Sentence>
<Sentence id="41" LabelDrug="Xarelto" section="34068-7">
<SentenceText>Switching from Anticoagulants other than Warfarin to XARELTO - For patients currently receiving an anticoagulant other than warfarin , start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug ( e.g. , low molecular weight heparin or non-warfarin oral anticoagulant ) and omit administration of the other anticoagulant .</SentenceText>
</Sentence>
<Sentence id="42" LabelDrug="Xarelto" section="34068-7">
<SentenceText>Switching from Warfarin to XARELTO - When switching patients from warfarin to XARELTO , discontinue warfarin and start XARELTO as soon as the International Normalized Ratio ( INR ) is below 3.0 to avoid periods of inadequate anticoagulation .</SentenceText>
</Sentence>
<Sentence id="43" LabelDrug="Xarelto" section="34068-7">
<SentenceText>Switching from XARELTO to Anticoagulants other than Warfarin - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset , discontinue XARELTO and give the first dose of the other anticoagulant ( oral or parenteral ) at the time that the next XARELTO dose would have been taken see Drug Interactions ( 7.4 ) .</SentenceText>
</Sentence>
<Sentence id="44" LabelDrug="Xarelto" section="34068-7">
<SentenceText>Switching from XARELTO to Warfarin - No clinical trial data are available to guide converting patients from XARELTO to warfarin .</SentenceText>
</Sentence>
<Sentence id="45" LabelDrug="Xarelto" section="34068-7">
<SentenceText>The recommended dose of XARELTO for the reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatment in patients at continued risk of DVT and/or PE is 10 mg taken orally once daily with or without food see Clinical Studies ( 14.3 ) .</SentenceText>
</Sentence>
<Sentence id="46" LabelDrug="Xarelto" section="34068-7">
<SentenceText>XARELTO affects INR , so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin .</SentenceText>
</Sentence>
<Sentence id="47" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor , pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk see Clinical Pharmacology ( 12.3 ) .</SentenceText>
</Sentence>
<Sentence id="48" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors ( e.g. , ketoconazole and ritonavir ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M7" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M2" type="Precipitant" span="107 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M4" type="Precipitant" span="64 4;87 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M6" type="Precipitant" span="124 9" str="ritonavir" code="N0000007423"/>
<Mention id="M8" type="Precipitant" span="73 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M7" precipitant="M2"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M7" precipitant="M4"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M7" precipitant="M6"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M7" precipitant="M8"/>
</Sentence>
<Sentence id="48" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors ( e.g. , ketoconazole and ritonavir ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M15" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M10" type="Precipitant" span="107 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M12" type="Precipitant" span="64 4;87 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M14" type="Precipitant" span="124 9" str="ritonavir" code="N0000007423"/>
<Mention id="M16" type="Precipitant" span="73 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I5" type="Unspecified interaction" trigger="M15" precipitant="M10"/>
<Interaction id="I6" type="Unspecified interaction" trigger="M15" precipitant="M12"/>
<Interaction id="I7" type="Unspecified interaction" trigger="M15" precipitant="M14"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M15" precipitant="M16"/>
</Sentence>
<Sentence id="48" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors ( e.g. , ketoconazole and ritonavir ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M23" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M18" type="Precipitant" span="107 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M20" type="Precipitant" span="64 4;87 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M22" type="Precipitant" span="124 9" str="ritonavir" code="N0000007423"/>
<Mention id="M24" type="Precipitant" span="73 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I9" type="Unspecified interaction" trigger="M23" precipitant="M18"/>
<Interaction id="I10" type="Unspecified interaction" trigger="M23" precipitant="M20"/>
<Interaction id="I11" type="Unspecified interaction" trigger="M23" precipitant="M22"/>
<Interaction id="I12" type="Unspecified interaction" trigger="M23" precipitant="M24"/>
</Sentence>
<Sentence id="48" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors ( e.g. , ketoconazole and ritonavir ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M31" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M26" type="Precipitant" span="107 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M28" type="Precipitant" span="64 4;87 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M30" type="Precipitant" span="124 9" str="ritonavir" code="N0000007423"/>
<Mention id="M32" type="Precipitant" span="73 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I13" type="Unspecified interaction" trigger="M31" precipitant="M26"/>
<Interaction id="I14" type="Unspecified interaction" trigger="M31" precipitant="M28"/>
<Interaction id="I15" type="Unspecified interaction" trigger="M31" precipitant="M30"/>
<Interaction id="I16" type="Unspecified interaction" trigger="M31" precipitant="M32"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M43" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M34" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M36" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M38" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M40" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M42" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M44" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I17" type="Unspecified interaction" trigger="M43" precipitant="M34"/>
<Interaction id="I18" type="Unspecified interaction" trigger="M43" precipitant="M36"/>
<Interaction id="I19" type="Unspecified interaction" trigger="M43" precipitant="M38"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M43" precipitant="M40"/>
<Interaction id="I21" type="Unspecified interaction" trigger="M43" precipitant="M42"/>
<Interaction id="I22" type="Unspecified interaction" trigger="M43" precipitant="M44"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M55" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M46" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M48" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M50" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M52" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M54" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M56" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I23" type="Unspecified interaction" trigger="M55" precipitant="M46"/>
<Interaction id="I24" type="Unspecified interaction" trigger="M55" precipitant="M48"/>
<Interaction id="I25" type="Unspecified interaction" trigger="M55" precipitant="M50"/>
<Interaction id="I26" type="Unspecified interaction" trigger="M55" precipitant="M52"/>
<Interaction id="I27" type="Unspecified interaction" trigger="M55" precipitant="M54"/>
<Interaction id="I28" type="Unspecified interaction" trigger="M55" precipitant="M56"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M67" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M58" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M60" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M62" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M64" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M66" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M68" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I29" type="Unspecified interaction" trigger="M67" precipitant="M58"/>
<Interaction id="I30" type="Unspecified interaction" trigger="M67" precipitant="M60"/>
<Interaction id="I31" type="Unspecified interaction" trigger="M67" precipitant="M62"/>
<Interaction id="I32" type="Unspecified interaction" trigger="M67" precipitant="M64"/>
<Interaction id="I33" type="Unspecified interaction" trigger="M67" precipitant="M66"/>
<Interaction id="I34" type="Unspecified interaction" trigger="M67" precipitant="M68"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M79" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M70" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M72" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M74" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M76" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M78" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M80" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I35" type="Unspecified interaction" trigger="M79" precipitant="M70"/>
<Interaction id="I36" type="Unspecified interaction" trigger="M79" precipitant="M72"/>
<Interaction id="I37" type="Unspecified interaction" trigger="M79" precipitant="M74"/>
<Interaction id="I38" type="Unspecified interaction" trigger="M79" precipitant="M76"/>
<Interaction id="I39" type="Unspecified interaction" trigger="M79" precipitant="M78"/>
<Interaction id="I40" type="Unspecified interaction" trigger="M79" precipitant="M80"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M91" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M82" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M84" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M86" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M88" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M90" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M92" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I41" type="Unspecified interaction" trigger="M91" precipitant="M82"/>
<Interaction id="I42" type="Unspecified interaction" trigger="M91" precipitant="M84"/>
<Interaction id="I43" type="Unspecified interaction" trigger="M91" precipitant="M86"/>
<Interaction id="I44" type="Unspecified interaction" trigger="M91" precipitant="M88"/>
<Interaction id="I45" type="Unspecified interaction" trigger="M91" precipitant="M90"/>
<Interaction id="I46" type="Unspecified interaction" trigger="M91" precipitant="M92"/>
</Sentence>
<Sentence id="49" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M103" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M94" type="Precipitant" span="103 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M96" type="Precipitant" span="62 4;85 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M98" type="Precipitant" span="119 9" str="phenytoin" code="N0000006023"/>
<Mention id="M100" type="Precipitant" span="131 8" str="rifampin" code="N0000006026"/>
<Mention id="M102" type="Precipitant" span="142 20" str="St.   John 's   wort" code="N0000022261"/>
<Mention id="M104" type="Precipitant" span="71 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I47" type="Unspecified interaction" trigger="M103" precipitant="M94"/>
<Interaction id="I48" type="Unspecified interaction" trigger="M103" precipitant="M96"/>
<Interaction id="I49" type="Unspecified interaction" trigger="M103" precipitant="M98"/>
<Interaction id="I50" type="Unspecified interaction" trigger="M103" precipitant="M100"/>
<Interaction id="I51" type="Unspecified interaction" trigger="M103" precipitant="M102"/>
<Interaction id="I52" type="Unspecified interaction" trigger="M103" precipitant="M104"/>
</Sentence>
<Sentence id="50" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk .</SentenceText>
<Mention id="M105" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M106" type="Precipitant" span="43 14" str="anticoagulants" code="N0000029110"/>
<Mention id="M107" type="SpecificInteraction" span="65 23" str="increased bleeding risk" code="131148009: Bleeding (finding)"/>
<Interaction id="I53" type="Pharmacodynamic interaction" trigger="M105" precipitant="M106" effect="M107"/>
</Sentence>
<Sentence id="51" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M120" type="Trigger" span="89 17" str="increase the risk"/>
<Mention id="M109" type="Precipitant" span="42 7" str="aspirin" code="N0000006582"/>
<Mention id="M122" type="SpecificInteraction" span="110 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M112" type="Precipitant" span="67 13" str="chronic NSAID" code="NO MAP"/>
<Mention id="M115" type="Precipitant" span="51 11" str="clopidogrel" code="N0000007277"/>
<Mention id="M118" type="Precipitant" span="20 10" str="enoxaparin" code="N0000006809"/>
<Mention id="M121" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Interaction id="I54" type="Pharmacodynamic interaction" trigger="M120" precipitant="M109" effect="M122"/>
<Interaction id="I55" type="Pharmacodynamic interaction" trigger="M120" precipitant="M112" effect="M122"/>
<Interaction id="I56" type="Pharmacodynamic interaction" trigger="M120" precipitant="M115" effect="M122"/>
<Interaction id="I57" type="Pharmacodynamic interaction" trigger="M120" precipitant="M118" effect="M122"/>
<Interaction id="I58" type="Pharmacodynamic interaction" trigger="M120" precipitant="M121" effect="M122"/>
</Sentence>
<Sentence id="51" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M135" type="Trigger" span="89 17" str="increase the risk"/>
<Mention id="M124" type="Precipitant" span="42 7" str="aspirin" code="N0000006582"/>
<Mention id="M137" type="SpecificInteraction" span="110 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M127" type="Precipitant" span="67 13" str="chronic NSAID" code="NO MAP"/>
<Mention id="M130" type="Precipitant" span="51 11" str="clopidogrel" code="N0000007277"/>
<Mention id="M133" type="Precipitant" span="20 10" str="enoxaparin" code="N0000006809"/>
<Mention id="M136" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Interaction id="I59" type="Pharmacodynamic interaction" trigger="M135" precipitant="M124" effect="M137"/>
<Interaction id="I60" type="Pharmacodynamic interaction" trigger="M135" precipitant="M127" effect="M137"/>
<Interaction id="I61" type="Pharmacodynamic interaction" trigger="M135" precipitant="M130" effect="M137"/>
<Interaction id="I62" type="Pharmacodynamic interaction" trigger="M135" precipitant="M133" effect="M137"/>
<Interaction id="I63" type="Pharmacodynamic interaction" trigger="M135" precipitant="M136" effect="M137"/>
</Sentence>
<Sentence id="51" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M150" type="Trigger" span="89 17" str="increase the risk"/>
<Mention id="M139" type="Precipitant" span="42 7" str="aspirin" code="N0000006582"/>
<Mention id="M152" type="SpecificInteraction" span="110 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M142" type="Precipitant" span="67 13" str="chronic NSAID" code="NO MAP"/>
<Mention id="M145" type="Precipitant" span="51 11" str="clopidogrel" code="N0000007277"/>
<Mention id="M148" type="Precipitant" span="20 10" str="enoxaparin" code="N0000006809"/>
<Mention id="M151" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Interaction id="I64" type="Pharmacodynamic interaction" trigger="M150" precipitant="M139" effect="M152"/>
<Interaction id="I65" type="Pharmacodynamic interaction" trigger="M150" precipitant="M142" effect="M152"/>
<Interaction id="I66" type="Pharmacodynamic interaction" trigger="M150" precipitant="M145" effect="M152"/>
<Interaction id="I67" type="Pharmacodynamic interaction" trigger="M150" precipitant="M148" effect="M152"/>
<Interaction id="I68" type="Pharmacodynamic interaction" trigger="M150" precipitant="M151" effect="M152"/>
</Sentence>
<Sentence id="51" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M165" type="Trigger" span="89 17" str="increase the risk"/>
<Mention id="M154" type="Precipitant" span="42 7" str="aspirin" code="N0000006582"/>
<Mention id="M167" type="SpecificInteraction" span="110 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M157" type="Precipitant" span="67 13" str="chronic NSAID" code="NO MAP"/>
<Mention id="M160" type="Precipitant" span="51 11" str="clopidogrel" code="N0000007277"/>
<Mention id="M163" type="Precipitant" span="20 10" str="enoxaparin" code="N0000006809"/>
<Mention id="M166" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Interaction id="I69" type="Pharmacodynamic interaction" trigger="M165" precipitant="M154" effect="M167"/>
<Interaction id="I70" type="Pharmacodynamic interaction" trigger="M165" precipitant="M157" effect="M167"/>
<Interaction id="I71" type="Pharmacodynamic interaction" trigger="M165" precipitant="M160" effect="M167"/>
<Interaction id="I72" type="Pharmacodynamic interaction" trigger="M165" precipitant="M163" effect="M167"/>
<Interaction id="I73" type="Pharmacodynamic interaction" trigger="M165" precipitant="M166" effect="M167"/>
</Sentence>
<Sentence id="51" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M180" type="Trigger" span="89 17" str="increase the risk"/>
<Mention id="M169" type="Precipitant" span="42 7" str="aspirin" code="N0000006582"/>
<Mention id="M182" type="SpecificInteraction" span="110 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M172" type="Precipitant" span="67 13" str="chronic NSAID" code="NO MAP"/>
<Mention id="M175" type="Precipitant" span="51 11" str="clopidogrel" code="N0000007277"/>
<Mention id="M178" type="Precipitant" span="20 10" str="enoxaparin" code="N0000006809"/>
<Mention id="M181" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Interaction id="I74" type="Pharmacodynamic interaction" trigger="M180" precipitant="M169" effect="M182"/>
<Interaction id="I75" type="Pharmacodynamic interaction" trigger="M180" precipitant="M172" effect="M182"/>
<Interaction id="I76" type="Pharmacodynamic interaction" trigger="M180" precipitant="M175" effect="M182"/>
<Interaction id="I77" type="Pharmacodynamic interaction" trigger="M180" precipitant="M178" effect="M182"/>
<Interaction id="I78" type="Pharmacodynamic interaction" trigger="M180" precipitant="M181" effect="M182"/>
</Sentence>
<Sentence id="52" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events .</SentenceText>
<Mention id="M186" type="Trigger" span="82 17" str="increase the risk"/>
<Mention id="M190" type="Precipitant" span="25 15" str="CYP3A4 inducers" code="N0000185506"/>
<Mention id="M188" type="SpecificInteraction" span="103 21" str="thromboembolic events" code="371039008: Thromboembolic disorder (disorder)"/>
<Mention id="M192" type="Precipitant" span="9 4;32 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M191" type="Trigger" span="41 17" str="decrease exposure"/>
<Interaction id="I79" type="Pharmacodynamic interaction" trigger="M186" precipitant="M190" effect="M188"/>
<Interaction id="I80" type="Pharmacodynamic interaction" trigger="M186" precipitant="M192" effect="M188"/>
<Interaction id="I81" type="Pharmacokinetic interaction" trigger="M191" precipitant="M190" effect="C54356"/>
<Interaction id="I82" type="Pharmacokinetic interaction" trigger="M191" precipitant="M192" effect="C54356"/>
</Sentence>
<Sentence id="52" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events .</SentenceText>
<Mention id="M196" type="Trigger" span="82 17" str="increase the risk"/>
<Mention id="M200" type="Precipitant" span="25 15" str="CYP3A4 inducers" code="N0000185506"/>
<Mention id="M198" type="SpecificInteraction" span="103 21" str="thromboembolic events" code="371039008: Thromboembolic disorder (disorder)"/>
<Mention id="M202" type="Precipitant" span="9 4;32 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M201" type="Trigger" span="41 17" str="decrease exposure"/>
<Interaction id="I83" type="Pharmacodynamic interaction" trigger="M196" precipitant="M200" effect="M198"/>
<Interaction id="I84" type="Pharmacodynamic interaction" trigger="M196" precipitant="M202" effect="M198"/>
<Interaction id="I85" type="Pharmacokinetic interaction" trigger="M201" precipitant="M200" effect="C54356"/>
<Interaction id="I86" type="Pharmacokinetic interaction" trigger="M201" precipitant="M202" effect="C54356"/>
</Sentence>
<Sentence id="52" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events .</SentenceText>
<Mention id="M206" type="Trigger" span="82 17" str="increase the risk"/>
<Mention id="M210" type="Precipitant" span="25 15" str="CYP3A4 inducers" code="N0000185506"/>
<Mention id="M208" type="SpecificInteraction" span="103 21" str="thromboembolic events" code="371039008: Thromboembolic disorder (disorder)"/>
<Mention id="M212" type="Precipitant" span="9 4;32 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M211" type="Trigger" span="41 17" str="decrease exposure"/>
<Interaction id="I87" type="Pharmacodynamic interaction" trigger="M206" precipitant="M210" effect="M208"/>
<Interaction id="I88" type="Pharmacodynamic interaction" trigger="M206" precipitant="M212" effect="M208"/>
<Interaction id="I89" type="Pharmacokinetic interaction" trigger="M211" precipitant="M210" effect="C54356"/>
<Interaction id="I90" type="Pharmacokinetic interaction" trigger="M211" precipitant="M212" effect="C54356"/>
</Sentence>
<Sentence id="52" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events .</SentenceText>
<Mention id="M216" type="Trigger" span="82 17" str="increase the risk"/>
<Mention id="M220" type="Precipitant" span="25 15" str="CYP3A4 inducers" code="N0000185506"/>
<Mention id="M218" type="SpecificInteraction" span="103 21" str="thromboembolic events" code="371039008: Thromboembolic disorder (disorder)"/>
<Mention id="M222" type="Precipitant" span="9 4;32 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M221" type="Trigger" span="41 17" str="decrease exposure"/>
<Interaction id="I91" type="Pharmacodynamic interaction" trigger="M216" precipitant="M220" effect="M218"/>
<Interaction id="I92" type="Pharmacodynamic interaction" trigger="M216" precipitant="M222" effect="M218"/>
<Interaction id="I93" type="Pharmacokinetic interaction" trigger="M221" precipitant="M220" effect="C54356"/>
<Interaction id="I94" type="Pharmacokinetic interaction" trigger="M221" precipitant="M222" effect="C54356"/>
</Sentence>
<Sentence id="53" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.</SentenceText>
<Mention id="M231" type="Trigger" span="57 5" str="Avoid"/>
<Mention id="M224" type="Precipitant" span="90 14" str="Anticoagulants" code="N0000029110"/>
<Mention id="M226" type="Precipitant" span="9 4;47 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M228" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M230" type="Precipitant" span="18 13;47 8" str="strong CYP3A4 | inducers" code="n0000185506"/>
<Mention id="M232" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I95" type="Unspecified interaction" trigger="M231" precipitant="M224"/>
<Interaction id="I96" type="Unspecified interaction" trigger="M231" precipitant="M226"/>
<Interaction id="I97" type="Unspecified interaction" trigger="M231" precipitant="M228"/>
<Interaction id="I98" type="Unspecified interaction" trigger="M231" precipitant="M230"/>
<Interaction id="I99" type="Unspecified interaction" trigger="M231" precipitant="M232"/>
</Sentence>
<Sentence id="53" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.</SentenceText>
<Mention id="M241" type="Trigger" span="57 5" str="Avoid"/>
<Mention id="M234" type="Precipitant" span="90 14" str="Anticoagulants" code="N0000029110"/>
<Mention id="M236" type="Precipitant" span="9 4;47 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M238" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M240" type="Precipitant" span="18 13;47 8" str="strong CYP3A4 | inducers" code="n0000185506"/>
<Mention id="M242" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I100" type="Unspecified interaction" trigger="M241" precipitant="M234"/>
<Interaction id="I101" type="Unspecified interaction" trigger="M241" precipitant="M236"/>
<Interaction id="I102" type="Unspecified interaction" trigger="M241" precipitant="M238"/>
<Interaction id="I103" type="Unspecified interaction" trigger="M241" precipitant="M240"/>
<Interaction id="I104" type="Unspecified interaction" trigger="M241" precipitant="M242"/>
</Sentence>
<Sentence id="53" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.</SentenceText>
<Mention id="M251" type="Trigger" span="57 5" str="Avoid"/>
<Mention id="M244" type="Precipitant" span="90 14" str="Anticoagulants" code="N0000029110"/>
<Mention id="M246" type="Precipitant" span="9 4;47 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M248" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M250" type="Precipitant" span="18 13;47 8" str="strong CYP3A4 | inducers" code="n0000185506"/>
<Mention id="M252" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I105" type="Unspecified interaction" trigger="M251" precipitant="M244"/>
<Interaction id="I106" type="Unspecified interaction" trigger="M251" precipitant="M246"/>
<Interaction id="I107" type="Unspecified interaction" trigger="M251" precipitant="M248"/>
<Interaction id="I108" type="Unspecified interaction" trigger="M251" precipitant="M250"/>
<Interaction id="I109" type="Unspecified interaction" trigger="M251" precipitant="M252"/>
</Sentence>
<Sentence id="53" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.</SentenceText>
<Mention id="M261" type="Trigger" span="57 5" str="Avoid"/>
<Mention id="M254" type="Precipitant" span="90 14" str="Anticoagulants" code="N0000029110"/>
<Mention id="M256" type="Precipitant" span="9 4;47 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M258" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M260" type="Precipitant" span="18 13;47 8" str="strong CYP3A4 | inducers" code="n0000185506"/>
<Mention id="M262" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I110" type="Unspecified interaction" trigger="M261" precipitant="M254"/>
<Interaction id="I111" type="Unspecified interaction" trigger="M261" precipitant="M256"/>
<Interaction id="I112" type="Unspecified interaction" trigger="M261" precipitant="M258"/>
<Interaction id="I113" type="Unspecified interaction" trigger="M261" precipitant="M260"/>
<Interaction id="I114" type="Unspecified interaction" trigger="M261" precipitant="M262"/>
</Sentence>
<Sentence id="53" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.</SentenceText>
<Mention id="M271" type="Trigger" span="57 5" str="Avoid"/>
<Mention id="M264" type="Precipitant" span="90 14" str="Anticoagulants" code="N0000029110"/>
<Mention id="M266" type="Precipitant" span="9 4;47 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M268" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M270" type="Precipitant" span="18 13;47 8" str="strong CYP3A4 | inducers" code="n0000185506"/>
<Mention id="M272" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I115" type="Unspecified interaction" trigger="M271" precipitant="M264"/>
<Interaction id="I116" type="Unspecified interaction" trigger="M271" precipitant="M266"/>
<Interaction id="I117" type="Unspecified interaction" trigger="M271" precipitant="M268"/>
<Interaction id="I118" type="Unspecified interaction" trigger="M271" precipitant="M270"/>
<Interaction id="I119" type="Unspecified interaction" trigger="M271" precipitant="M272"/>
</Sentence>
<Sentence id="54" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding .</SentenceText>
<Mention id="M278" type="Trigger" span="84 17" str="increase the risk"/>
<Mention id="M277" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M280" type="SpecificInteraction" span="105 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M281" type="Trigger" span="43 17" str="increase exposure"/>
<Mention id="M282" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I120" type="Pharmacodynamic interaction" trigger="M278" precipitant="M277" effect="M280"/>
<Interaction id="I121" type="Pharmacokinetic interaction" trigger="M281" precipitant="M277" effect="C54355"/>
<Interaction id="I122" type="Pharmacodynamic interaction" trigger="M278" precipitant="M282" effect="M280"/>
<Interaction id="I123" type="Pharmacokinetic interaction" trigger="M281" precipitant="M282" effect="C54355"/>
</Sentence>
<Sentence id="54" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding .</SentenceText>
<Mention id="M288" type="Trigger" span="84 17" str="increase the risk"/>
<Mention id="M287" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M290" type="SpecificInteraction" span="105 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M291" type="Trigger" span="43 17" str="increase exposure"/>
<Mention id="M292" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I124" type="Pharmacodynamic interaction" trigger="M288" precipitant="M287" effect="M290"/>
<Interaction id="I125" type="Pharmacokinetic interaction" trigger="M291" precipitant="M287" effect="C54355"/>
<Interaction id="I126" type="Pharmacodynamic interaction" trigger="M288" precipitant="M292" effect="M290"/>
<Interaction id="I127" type="Pharmacokinetic interaction" trigger="M291" precipitant="M292" effect="C54355"/>
</Sentence>
<Sentence id="54" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding .</SentenceText>
<Mention id="M298" type="Trigger" span="84 17" str="increase the risk"/>
<Mention id="M297" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M300" type="SpecificInteraction" span="105 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M301" type="Trigger" span="43 17" str="increase exposure"/>
<Mention id="M302" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I128" type="Pharmacodynamic interaction" trigger="M298" precipitant="M297" effect="M300"/>
<Interaction id="I129" type="Pharmacokinetic interaction" trigger="M301" precipitant="M297" effect="C54355"/>
<Interaction id="I130" type="Pharmacodynamic interaction" trigger="M298" precipitant="M302" effect="M300"/>
<Interaction id="I131" type="Pharmacokinetic interaction" trigger="M301" precipitant="M302" effect="C54355"/>
</Sentence>
<Sentence id="54" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding .</SentenceText>
<Mention id="M308" type="Trigger" span="84 17" str="increase the risk"/>
<Mention id="M307" type="Precipitant" span="9 4;32 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M310" type="SpecificInteraction" span="105 8" str="bleeding" code="131148009: Bleeding (finding)"/>
<Mention id="M311" type="Trigger" span="43 17" str="increase exposure"/>
<Mention id="M312" type="Precipitant" span="18 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I132" type="Pharmacodynamic interaction" trigger="M308" precipitant="M307" effect="M310"/>
<Interaction id="I133" type="Pharmacokinetic interaction" trigger="M311" precipitant="M307" effect="C54355"/>
<Interaction id="I134" type="Pharmacodynamic interaction" trigger="M308" precipitant="M312" effect="M310"/>
<Interaction id="I135" type="Pharmacokinetic interaction" trigger="M311" precipitant="M312" effect="C54355"/>
</Sentence>
<Sentence id="55" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Moderate CYP3A4 Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M317" type="Trigger" span="104 18" str="should not be used"/>
<Mention id="M314" type="Precipitant" span="244 12" str="erythromycin" code="N0000007133"/>
<Mention id="M316" type="Precipitant" span="210 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M318" type="Precipitant" span="26 4;226 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I136" type="Unspecified interaction" trigger="M317" precipitant="M314"/>
<Interaction id="I137" type="Unspecified interaction" trigger="M317" precipitant="M316"/>
<Interaction id="I138" type="Unspecified interaction" trigger="M317" precipitant="M318"/>
</Sentence>
<Sentence id="55" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Moderate CYP3A4 Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M323" type="Trigger" span="104 18" str="should not be used"/>
<Mention id="M320" type="Precipitant" span="244 12" str="erythromycin" code="N0000007133"/>
<Mention id="M322" type="Precipitant" span="210 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M324" type="Precipitant" span="26 4;226 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I139" type="Unspecified interaction" trigger="M323" precipitant="M320"/>
<Interaction id="I140" type="Unspecified interaction" trigger="M323" precipitant="M322"/>
<Interaction id="I141" type="Unspecified interaction" trigger="M323" precipitant="M324"/>
</Sentence>
<Sentence id="55" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Moderate CYP3A4 Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M329" type="Trigger" span="104 18" str="should not be used"/>
<Mention id="M326" type="Precipitant" span="244 12" str="erythromycin" code="N0000007133"/>
<Mention id="M328" type="Precipitant" span="210 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M330" type="Precipitant" span="26 4;226 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I142" type="Unspecified interaction" trigger="M329" precipitant="M326"/>
<Interaction id="I143" type="Unspecified interaction" trigger="M329" precipitant="M328"/>
<Interaction id="I144" type="Unspecified interaction" trigger="M329" precipitant="M330"/>
</Sentence>
<Sentence id="56" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Strong CYP3A4 Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M337" type="Trigger" span="60 5" str="Avoid"/>
<Mention id="M332" type="Precipitant" span="165 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M334" type="Precipitant" span="26 4;147 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M336" type="Precipitant" span="182 9" str="ritonavir" code="N0000007423"/>
<Mention id="M338" type="Precipitant" span="133 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I145" type="Unspecified interaction" trigger="M337" precipitant="M332"/>
<Interaction id="I146" type="Unspecified interaction" trigger="M337" precipitant="M334"/>
<Interaction id="I147" type="Unspecified interaction" trigger="M337" precipitant="M336"/>
<Interaction id="I148" type="Unspecified interaction" trigger="M337" precipitant="M338"/>
</Sentence>
<Sentence id="56" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Strong CYP3A4 Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M345" type="Trigger" span="60 5" str="Avoid"/>
<Mention id="M340" type="Precipitant" span="165 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M342" type="Precipitant" span="26 4;147 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M344" type="Precipitant" span="182 9" str="ritonavir" code="N0000007423"/>
<Mention id="M346" type="Precipitant" span="133 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I149" type="Unspecified interaction" trigger="M345" precipitant="M340"/>
<Interaction id="I150" type="Unspecified interaction" trigger="M345" precipitant="M342"/>
<Interaction id="I151" type="Unspecified interaction" trigger="M345" precipitant="M344"/>
<Interaction id="I152" type="Unspecified interaction" trigger="M345" precipitant="M346"/>
</Sentence>
<Sentence id="56" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Strong CYP3A4 Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M353" type="Trigger" span="60 5" str="Avoid"/>
<Mention id="M348" type="Precipitant" span="165 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M350" type="Precipitant" span="26 4;147 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M352" type="Precipitant" span="182 9" str="ritonavir" code="N0000007423"/>
<Mention id="M354" type="Precipitant" span="133 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I153" type="Unspecified interaction" trigger="M353" precipitant="M348"/>
<Interaction id="I154" type="Unspecified interaction" trigger="M353" precipitant="M350"/>
<Interaction id="I155" type="Unspecified interaction" trigger="M353" precipitant="M352"/>
<Interaction id="I156" type="Unspecified interaction" trigger="M353" precipitant="M354"/>
</Sentence>
<Sentence id="56" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Interaction with Combined P-gp and Strong CYP3A4 Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M361" type="Trigger" span="60 5" str="Avoid"/>
<Mention id="M356" type="Precipitant" span="165 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M358" type="Precipitant" span="26 4;147 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M360" type="Precipitant" span="182 9" str="ritonavir" code="N0000007423"/>
<Mention id="M362" type="Precipitant" span="133 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I157" type="Unspecified interaction" trigger="M361" precipitant="M356"/>
<Interaction id="I158" type="Unspecified interaction" trigger="M361" precipitant="M358"/>
<Interaction id="I159" type="Unspecified interaction" trigger="M361" precipitant="M360"/>
<Interaction id="I160" type="Unspecified interaction" trigger="M361" precipitant="M362"/>
</Sentence>
<Sentence id="57" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].</SentenceText>
<Mention id="M369" type="Trigger" span="9 8;22 17" str="evaluate | signs or symptoms"/>
<Mention id="M364" type="Precipitant" span="97 7" str="aspirin" code="N0000006582"/>
<Mention id="M371" type="SpecificInteraction" span="43 10" str="blood loss" code="131148009: Bleeding (finding)"/>
<Mention id="M367" type="Precipitant" span="148 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M370" type="Precipitant" span="112 31" str="platelet aggregation inhibitors" code="N0000029299"/>
<Interaction id="I161" type="Pharmacodynamic interaction" trigger="M369" precipitant="M364" effect="M371"/>
<Interaction id="I162" type="Pharmacodynamic interaction" trigger="M369" precipitant="M367" effect="M371"/>
<Interaction id="I163" type="Pharmacodynamic interaction" trigger="M369" precipitant="M370" effect="M371"/>
</Sentence>
<Sentence id="57" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].</SentenceText>
<Mention id="M378" type="Trigger" span="9 8;22 17" str="evaluate | signs or symptoms"/>
<Mention id="M373" type="Precipitant" span="97 7" str="aspirin" code="N0000006582"/>
<Mention id="M380" type="SpecificInteraction" span="43 10" str="blood loss" code="131148009: Bleeding (finding)"/>
<Mention id="M376" type="Precipitant" span="148 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M379" type="Precipitant" span="112 31" str="platelet aggregation inhibitors" code="N0000029299"/>
<Interaction id="I164" type="Pharmacodynamic interaction" trigger="M378" precipitant="M373" effect="M380"/>
<Interaction id="I165" type="Pharmacodynamic interaction" trigger="M378" precipitant="M376" effect="M380"/>
<Interaction id="I166" type="Pharmacodynamic interaction" trigger="M378" precipitant="M379" effect="M380"/>
</Sentence>
<Sentence id="57" LabelDrug="Xarelto" section="34073-7">
<SentenceText>Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].</SentenceText>
<Mention id="M387" type="Trigger" span="9 8;22 17" str="evaluate | signs or symptoms"/>
<Mention id="M382" type="Precipitant" span="97 7" str="aspirin" code="N0000006582"/>
<Mention id="M389" type="SpecificInteraction" span="43 10" str="blood loss" code="131148009: Bleeding (finding)"/>
<Mention id="M385" type="Precipitant" span="148 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M388" type="Precipitant" span="112 31" str="platelet aggregation inhibitors" code="N0000029299"/>
<Interaction id="I167" type="Pharmacodynamic interaction" trigger="M387" precipitant="M382" effect="M389"/>
<Interaction id="I168" type="Pharmacodynamic interaction" trigger="M387" precipitant="M385" effect="M389"/>
<Interaction id="I169" type="Pharmacodynamic interaction" trigger="M387" precipitant="M388" effect="M389"/>
</Sentence>
<Sentence id="58" LabelDrug="Xarelto" section="34073-7">
<SentenceText>XARELTO should not be used in patients with CrCl 15 to 80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors ( e.g. , erythromycin ) unless the potential benefit justifies the potential risk see Warnings and Precautions ( 5.4 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M394" type="Trigger" span="8 18" str="should not be used"/>
<Mention id="M391" type="Precipitant" span="149 12" str="erythromycin" code="N0000007133"/>
<Mention id="M393" type="Precipitant" span="113 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M395" type="Precipitant" span="104 4;129 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I170" type="Unspecified interaction" trigger="M394" precipitant="M391"/>
<Interaction id="I171" type="Unspecified interaction" trigger="M394" precipitant="M393"/>
<Interaction id="I172" type="Unspecified interaction" trigger="M394" precipitant="M395"/>
</Sentence>
<Sentence id="58" LabelDrug="Xarelto" section="34073-7">
<SentenceText>XARELTO should not be used in patients with CrCl 15 to 80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors ( e.g. , erythromycin ) unless the potential benefit justifies the potential risk see Warnings and Precautions ( 5.4 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M400" type="Trigger" span="8 18" str="should not be used"/>
<Mention id="M397" type="Precipitant" span="149 12" str="erythromycin" code="N0000007133"/>
<Mention id="M399" type="Precipitant" span="113 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M401" type="Precipitant" span="104 4;129 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I173" type="Unspecified interaction" trigger="M400" precipitant="M397"/>
<Interaction id="I174" type="Unspecified interaction" trigger="M400" precipitant="M399"/>
<Interaction id="I175" type="Unspecified interaction" trigger="M400" precipitant="M401"/>
</Sentence>
<Sentence id="58" LabelDrug="Xarelto" section="34073-7">
<SentenceText>XARELTO should not be used in patients with CrCl 15 to 80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors ( e.g. , erythromycin ) unless the potential benefit justifies the potential risk see Warnings and Precautions ( 5.4 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M406" type="Trigger" span="8 18" str="should not be used"/>
<Mention id="M403" type="Precipitant" span="149 12" str="erythromycin" code="N0000007133"/>
<Mention id="M405" type="Precipitant" span="113 26" str="moderate CYP3A4 inhibitors" code="n0000182141"/>
<Mention id="M407" type="Precipitant" span="104 4;129 10" str="P-gp | inhibitors" code="n0000185503"/>
<Interaction id="I176" type="Unspecified interaction" trigger="M406" precipitant="M403"/>
<Interaction id="I177" type="Unspecified interaction" trigger="M406" precipitant="M405"/>
<Interaction id="I178" type="Unspecified interaction" trigger="M406" precipitant="M407"/>
</Sentence>
<Sentence id="59" LabelDrug="Xarelto" section="43685-7">
<SentenceText>A specific antidote for rivaroxaban is not available .</SentenceText>
</Sentence>
<Sentence id="60" LabelDrug="Xarelto" section="43685-7">
<SentenceText>An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients .</SentenceText>
</Sentence>
<Sentence id="61" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A4 inducers see Drug Interactions ( 7.3 ) .</SentenceText>
<Mention id="M410" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M409" type="Precipitant" span="68 4;91 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M411" type="Precipitant" span="77 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I179" type="Unspecified interaction" trigger="M410" precipitant="M409"/>
<Interaction id="I180" type="Unspecified interaction" trigger="M410" precipitant="M411"/>
</Sentence>
<Sentence id="61" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A4 inducers see Drug Interactions ( 7.3 ) .</SentenceText>
<Mention id="M414" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M413" type="Precipitant" span="68 4;91 8" str="P-gp | inducers" code="n0000191264"/>
<Mention id="M415" type="Precipitant" span="77 22" str="strong CYP3A4 inducers" code="n0000185506"/>
<Interaction id="I181" type="Unspecified interaction" trigger="M414" precipitant="M413"/>
<Interaction id="I182" type="Unspecified interaction" trigger="M414" precipitant="M415"/>
</Sentence>
<Sentence id="62" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A4 inhibitors see Drug Interactions ( 7.2 ) .</SentenceText>
<Mention id="M418" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M417" type="Precipitant" span="53 4;76 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M419" type="Precipitant" span="62 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I183" type="Unspecified interaction" trigger="M418" precipitant="M417"/>
<Interaction id="I184" type="Unspecified interaction" trigger="M418" precipitant="M419"/>
</Sentence>
<Sentence id="62" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A4 inhibitors see Drug Interactions ( 7.2 ) .</SentenceText>
<Mention id="M422" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M421" type="Precipitant" span="53 4;76 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M423" type="Precipitant" span="62 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I185" type="Unspecified interaction" trigger="M422" precipitant="M421"/>
<Interaction id="I186" type="Unspecified interaction" trigger="M422" precipitant="M423"/>
</Sentence>
<Sentence id="63" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Concomitant use of drugs that are known combined P-gp and strong CYP3A4 inhibitors increases rivaroxaban exposure and may increase bleeding risk see Drug Interactions ( 7.2 ) .</SentenceText>
<Mention id="M426" type="Trigger" span="83 9;105 8" str="increases | exposure"/>
<Mention id="M425" type="Precipitant" span="49 4;72 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M427" type="Precipitant" span="58 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I187" type="Pharmacokinetic interaction" trigger="M426" precipitant="M425" effect="C54355"/>
<Interaction id="I188" type="Pharmacokinetic interaction" trigger="M426" precipitant="M427" effect="C54355"/>
</Sentence>
<Sentence id="63" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Concomitant use of drugs that are known combined P-gp and strong CYP3A4 inhibitors increases rivaroxaban exposure and may increase bleeding risk see Drug Interactions ( 7.2 ) .</SentenceText>
<Mention id="M430" type="Trigger" span="83 9;105 8" str="increases | exposure"/>
<Mention id="M429" type="Precipitant" span="49 4;72 10" str="P-gp | inhibitors" code="n0000185503"/>
<Mention id="M431" type="Precipitant" span="58 24" str="strong CYP3A4 inhibitors" code="n0000182141"/>
<Interaction id="I189" type="Pharmacokinetic interaction" trigger="M430" precipitant="M429" effect="C54355"/>
<Interaction id="I190" type="Pharmacokinetic interaction" trigger="M430" precipitant="M431" effect="C54355"/>
</Sentence>
<Sentence id="64" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy .</SentenceText>
</Sentence>
<Sentence id="65" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Premature discontinuation of any oral anticoagulant , including XARELTO , in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .</SentenceText>
</Sentence>
<Sentence id="66" LabelDrug="Xarelto" section="43685-7">
<SentenceText>Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Unspecified interaction" precipitant="ketoconazole" precipitantCode="N0000007319"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="p-gp | inhibitors" precipitantCode="n0000185503" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="p-gp | inhibitors" precipitantCode="n0000185503" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="p-gp | inhibitors" precipitantCode="n0000185503"/>
<LabelInteraction type="Unspecified interaction" precipitant="ritonavir" precipitantCode="N0000007423"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="n0000182141" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="n0000182141" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="n0000182141"/>
<LabelInteraction type="Unspecified interaction" precipitant="carbamazepine" precipitantCode="N0000007470"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="p-gp | inducers" precipitantCode="n0000191264" effect="371039008: Thromboembolic disorder (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="p-gp | inducers" precipitantCode="n0000191264" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="p-gp | inducers" precipitantCode="n0000191264"/>
<LabelInteraction type="Unspecified interaction" precipitant="phenytoin" precipitantCode="N0000006023"/>
<LabelInteraction type="Unspecified interaction" precipitant="rifampin" precipitantCode="N0000006026"/>
<LabelInteraction type="Unspecified interaction" precipitant="st.   john 's   wort" precipitantCode="N0000022261"/>
<LabelInteraction type="Unspecified interaction" precipitant="strong cyp3a4 inducers" precipitantCode="n0000185506"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="anticoagulants" precipitantCode="N0000029110" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Unspecified interaction" precipitant="anticoagulants" precipitantCode="N0000029110"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="chronic nsaid" precipitantCode="NO MAP" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clopidogrel" precipitantCode="N0000007277" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="enoxaparin" precipitantCode="N0000006809" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="warfarin" precipitantCode="N0000006403" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a4 inducers" precipitantCode="N0000185506" effect="371039008: Thromboembolic disorder (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a4 inducers" precipitantCode="N0000185506" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="strong cyp3a4 | inducers" precipitantCode="n0000185506"/>
<LabelInteraction type="Unspecified interaction" precipitant="erythromycin" precipitantCode="N0000007133"/>
<LabelInteraction type="Unspecified interaction" precipitant="moderate cyp3a4 inhibitors" precipitantCode="n0000182141"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="platelet aggregation inhibitors" precipitantCode="N0000029299" effect="131148009: Bleeding (finding)"/>

</LabelInteractions></Label>